Valneva IPO Presentation Deck
Company in Strong Position to Scale its Business
Valneva Has a Strong Cash Position
UK Government COVID-19 collaboration
including instalments to mitigate capex
and working capital related to clinical trials
and inventory build-up
Finished up 2020 with €204 million in cash Access to largest life science capital market
/ cash-equivalents
■ Provides capital to accelerate R&D programs
Supplements capital received from UK
COVID-19 deal
Commercial business supported by US
Military contract revenues
V
¹Market Data 20-04-2021
US IPO Is Part of Capital Formation Strategy
Valneva - Roadshow Presentation
- Opportunity to build R&D pipeline as
current programs advance
Valneva (VLA): Approximately 93m Shares in Issue, and a Market Cap of
Approximately €1,200m¹
Enables potential opportunistic plays to
acquire other vaccine assets
April 2021
37View entire presentation